May 25 (Reuters) - Trillium Therapeutics Inc TRIL.TO
* Trillium announces proposed public offering
* Trillium therapeutics inc - intends to use net proceeds of offering to advance and expand current phase 1 trial of sirpfc
* Trillium therapeutics - to use net proceeds to initiate , conduct a phase 1 trial for tti-622 with dose escalation and expansion phase focused on combination treatment Source text for Eikon: ID:nCCNS5VKqa Further company coverage: TRIL.TO